BR112018072797A2 - veículos farmacêuticos contendo mirnas para uso no tratamento de doenças fibróticas causadas por hiperglicemia - Google Patents

veículos farmacêuticos contendo mirnas para uso no tratamento de doenças fibróticas causadas por hiperglicemia

Info

Publication number
BR112018072797A2
BR112018072797A2 BR112018072797A BR112018072797A BR112018072797A2 BR 112018072797 A2 BR112018072797 A2 BR 112018072797A2 BR 112018072797 A BR112018072797 A BR 112018072797A BR 112018072797 A BR112018072797 A BR 112018072797A BR 112018072797 A2 BR112018072797 A2 BR 112018072797A2
Authority
BR
Brazil
Prior art keywords
hyperglycemia
treatment
mirn
disorders caused
containing pharmaceutical
Prior art date
Application number
BR112018072797A
Other languages
English (en)
Inventor
Camussi Giovanni
Felice Brizzi Maria
Original Assignee
Unicyte Ev Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unicyte Ev Ag filed Critical Unicyte Ev Ag
Publication of BR112018072797A2 publication Critical patent/BR112018072797A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Abstract

a invenção se refere a uma aplicação terapêutica inovadora de veículos farmaceuticamente aceitáveis contendo mir222. em particular, a invenção se refere ao uso de vesículas extracelulares (ves), que contêm o microrna mir222, no tratamento de doença fibrótica causada por hiperglicemia, como nefropatia diabética e/ou fibrose renal.
BR112018072797A 2016-05-06 2017-05-04 veículos farmacêuticos contendo mirnas para uso no tratamento de doenças fibróticas causadas por hiperglicemia BR112018072797A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16168546 2016-05-06
PCT/EP2017/060612 WO2017191234A1 (en) 2016-05-06 2017-05-04 Pharmaceutical carriers containing mirnas for use in the treatment of fibrotic diseases caused by hyperglycemia

Publications (1)

Publication Number Publication Date
BR112018072797A2 true BR112018072797A2 (pt) 2019-03-12

Family

ID=56008484

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018072797A BR112018072797A2 (pt) 2016-05-06 2017-05-04 veículos farmacêuticos contendo mirnas para uso no tratamento de doenças fibróticas causadas por hiperglicemia

Country Status (13)

Country Link
US (2) US10716813B2 (pt)
EP (2) EP3452100B1 (pt)
JP (1) JP7011605B2 (pt)
KR (1) KR102467150B1 (pt)
CN (1) CN109195637B (pt)
AU (1) AU2017260660B2 (pt)
BR (1) BR112018072797A2 (pt)
CA (1) CA3022921A1 (pt)
DK (1) DK3452100T3 (pt)
EA (1) EA037967B1 (pt)
ES (1) ES2861650T3 (pt)
PL (1) PL3452100T3 (pt)
WO (1) WO2017191234A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI629990B (zh) 2010-05-12 2018-07-21 英瑞金公司 生物活性腎細胞
JP7372917B2 (ja) 2017-12-14 2023-11-01 ユニシテ エーファウ アクチェンゲゼルシャフト ｍｉＲＮＡを含有する、腎癌の処置における使用のための薬学的キャリア
WO2020047071A1 (en) * 2018-08-31 2020-03-05 Timothy Bertram Compositions comprising cell-derived vesicles and uses thereof
JP2022536145A (ja) * 2019-06-10 2022-08-12 ユニシテ エーファウ アクチェンゲゼルシャフト 細胞老化を低下させるためのヒト肝臓幹細胞由来の細胞外小胞（ｈｌｓｃ－ｅｖ）
CN115463107A (zh) * 2021-06-10 2022-12-13 中山大学 一种工程化囊泡的制备方法及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004504389A (ja) * 2000-07-13 2004-02-12 アルテオン　インコーポレーテッド シアノメチル置換化チアゾリウム及びイミダゾリウム、並びにタンパク質老化と関連する疾患の治療
WO2006126219A1 (en) 2005-05-26 2006-11-30 Fresenius Medical Care Deutschland G.M.B.H. Liver progenitor cells
US9085778B2 (en) 2006-05-03 2015-07-21 VL27, Inc. Exosome transfer of nucleic acids to cells
AU2009215934C1 (en) * 2008-02-22 2014-05-08 Agency For Science, Technology And Research (A*Star) Mesenchymal stem cell particles
US8486909B2 (en) * 2009-06-24 2013-07-16 Board Of Regents Of The University Of Nebraska Compositions and methods for the diagnosis and treatment of inflammatory disorders and fibrotic disease
US8648017B2 (en) * 2009-11-04 2014-02-11 Diamir, Llc Methods of using small RNA from bodily fluids for diagnosis and monitoring of neurodegenerative diseases
TWI629990B (zh) 2010-05-12 2018-07-21 英瑞金公司 生物活性腎細胞
WO2012020307A2 (en) * 2010-08-13 2012-02-16 The University Court Of The University Of Glasgow Therapeutic uses of microvesicles and related micrornas
AU2013245406B2 (en) * 2012-04-03 2017-07-20 Reneuron Limited Stem cell microparticles
CN104703609B (zh) * 2012-07-19 2019-02-19 兰诺龙有限公司 干细胞微粒
JP6474394B2 (ja) * 2013-07-05 2019-02-27 ユニベルシテ カトリック ドゥ ルーベン ヒト成体肝臓幹細胞由来の馴化培地および肝臓障害の治療におけるその使用
GB201317887D0 (en) 2013-10-09 2013-11-20 Reneuron Ltd Product
US20170298352A1 (en) * 2014-09-30 2017-10-19 Research Institute at Nationwide Children's Hospit al Compositions and methods for treating hepatic fibrosis
CN108025016A (zh) * 2015-09-16 2018-05-11 国立大学法人东北大学 核酸分子

Also Published As

Publication number Publication date
EP3452100A1 (en) 2019-03-13
CN109195637A (zh) 2019-01-11
PL3452100T3 (pl) 2021-07-19
EP3777897A2 (en) 2021-02-17
CA3022921A1 (en) 2017-11-09
ES2861650T3 (es) 2021-10-06
JP2019514964A (ja) 2019-06-06
KR20190005209A (ko) 2019-01-15
CN109195637B (zh) 2022-08-09
AU2017260660B2 (en) 2023-12-21
EA037967B1 (ru) 2021-06-16
US20190209619A1 (en) 2019-07-11
US11110130B2 (en) 2021-09-07
KR102467150B1 (ko) 2022-11-14
US10716813B2 (en) 2020-07-21
US20200222467A1 (en) 2020-07-16
EP3777897A3 (en) 2021-06-09
AU2017260660A1 (en) 2018-12-20
DK3452100T3 (da) 2021-03-08
EA201892536A1 (ru) 2019-04-30
EP3452100B1 (en) 2020-12-16
WO2017191234A1 (en) 2017-11-09
JP7011605B2 (ja) 2022-01-26

Similar Documents

Publication Publication Date Title
BR112018072797A2 (pt) veículos farmacêuticos contendo mirnas para uso no tratamento de doenças fibróticas causadas por hiperglicemia
CL2014003388A1 (es) Compuestos derivados de triazolona, como inhibidores de mpges-1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, util para el tratamiento de inflamacion, asma, epoc, artritis, enfermedad de parkinson y enfermedades autoinmunes, entre otras enfermedades.
PH12016501966B1 (en) Compounds and compositions as toll-like receptor 7 agonists
CL2015000851A1 (es) Compuestos derivados de piridina, inhibidores de gdf-8; composicion farmaceutica; metodo para tratar trastornos o enfermedades tales como distrofia muscular, osteoporosis, obesidad, diabetes tipo 2, tolerancia alterada de la glucosa, entre otras.
BR112016023039A2 (pt) agonistas duplos dos receptores de glp-1 / glucagon derivados de exendina-4
EP3294323A4 (en) ADENO-ASSOCIATED VIRUS FOR THE RELEASE OF THERAPEUTICS IN THE CENTRAL NERVOUS SYSTEM
BR112016017564A8 (pt) métodos e composições para matar células senescentes e para tratar doenças e transtornos associados à senescência
GT201500243A (es) Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina
CU20140048A7 (es) Novedosos derivados de purina útiles en el tratamiento del cáncer y trastornos neurodegenerativos
BR112014014124A2 (pt) Moduladores do receptor de estrogênio fluorados e usos dos mesmos
GT201400085A (es) Profármaco de adrenomedulina basado en polietilenglicol y su uso
AU2012205878A8 (en) miRNA for treating diseases and conditions associated with neo-angiogenesis
MX2017002816A (es) Derivados de pirazolopiridina y su uso en terapia.
CL2014000210A1 (es) Una composicion de prodroga que comprende al menos un conjugado de metilfenidato; kit farmaceutico que la comprende, util para el tratamiento de una enfermedad o condicion que requiere estimulacion del sistema nervioso tal como un trastorno de hiperactividad con deficit de atencion y depresion.
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
CL2015001318A1 (es) Compuestos derivados de pirazina, agonistas del receptor cb2; proceso de obtencion; composicion farmaceutica y el uso en el tratamiento de enfermedades tales como aterosclerosis, glaucoma, diabetes, entre otras.
PH12016500978A1 (en) Piperazine derivatives having multimodal activity against pain
ECSP14002542A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
BR112017000898A2 (pt) oritavancina de alta pureza e método de produção da mesma
EP3398605A4 (en) MEDICAL COMPOSITION FOR IMPROVING THE FORECAST AFTER RECOVERING A PATIENT'S OWN HEARTBEAT
EP3156055A4 (en) Pharmaceutical composition for preventing or treating muscular weakness-related diseases, containing butylpyridinium or derivative thereof
CL2014003185A1 (es) Preformulacion de baja viscosidad que comprende pasireotida, agonista del receptor de somatostatina; proceso de preparacion de la preformulacion; kit farmaceutico; uso para tratar enfermedad de cushing o acromegalia.
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
MX2018002354A (es) Métodos para el tratamiento de una enfermedad poliquística renal.
BR112014020008A8 (pt) composição farmacêutica, uso da mesma, e, processo para a fabricação de uma formulação.

Legal Events

Date Code Title Description
B15V Prolongation of time limit allowed

Free format text: TENDO EM VISTA A PORTARIA INPI PR NO 120 DE 16/03/2020, PORTARIA INPI PR NO 161 DE 13/04/2020; PORTARIA INPI PR NO 166 DE 27/04/2020 E PORTARIA INPI PR NO 179 DE 11/05/2020, QUANTO A SUSPENSAO DOS PRAZOS VENCIDOS ENTRE 16/03/2020 A 31/05/2020, DEVOLVE-SE O PRAZO NESSE PEDIDO COM RELACAO A SOLICITACAO DO PEDIDO DE EXAME.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]